PRCC (proline rich mitotic checkpoint control factor) is a nuclear protein predicted to regulate cell cycle progression through interaction with MAD2L2 [UniProt]. The gene is located on chromosome 1 and localizes to nuclear specks and the nucleoplasm, where it functions in protein binding and cell cycle regulation [GO Annotations]. While the provided abstracts do not directly characterize PRCC's molecular mechanism or primary biochemical function, they do establish PRCC's clinical significance in renal cell carcinoma (RCC). PRCC is notable as a fusion partner in papillary renal cell carcinoma (pRCC), forming the PRCC-TFE3 fusion protein in TFE3 translocation RCC (TFE3 tRCC). The PRCC-TFE3 fusion constitutively activates PRKN expression, leading to PINK1-PRKN-dependent mitophagy that promotes cell survival under mitochondrial oxidative stress and enhances proliferation through decreased mitochondrial ROS formation 1. Additionally, PRCC-TFE3 fusion accelerates mitochondrial turnover via PPARGC1A/PGC1α-NRF1 activation 1. pRCC represents the second most common renal carcinoma subtype with heterogeneous molecular features and prognosis 2, and metastatic pRCC carries particularly poor prognosis compared to other non-clear cell RCC subtypes 3. These findings suggest PRCC's involvement in oncogenic transformation through gene fusion mechanisms.